Discovery of YS-363 as a highly potent, selective, and orally efficacious EGFR inhibitor

The Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the standard first-line therapy for EGFR-mutated NSCLC. However, long-term clinical treatment often leads to acquired drug resistance, making NSCLC refractory. Therefore, it is essential to design new EGFR inhibitors a...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Biomedicine & pharmacotherapy 2023-11, Vol.167, p.115491-115491, Article 115491
Hauptverfasser:	He, Pengxing, Jing, Jing, Du, Linna, Zhang, Xuyang, Ren, Yufei, Yang, Han, Yu, Bin, Liu, Hongmin
Format:	Artikel
Sprache:	eng
Schlagworte:	Antitumor activity EGFR inhibitor EGFR kinase YS-363
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!